Physician

Kathleen Bridget Doughney, MD

According to 2025 Medicare claims, Kathleen Doughney, MD (NPI: 1093729287) practices hematology/oncology in the Deltona-Daytona Beach-Ormond Beach, FL market, with the plurality of this provider's patient population coming from Volusia, FL. This provider's primary affiliated billing organization is FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (NPI: 1760590962; TIN: 65-0825133) and primary practice location at 32174-8179. Doughney is affiliated with the Complete Health Accountable Care LLC (ACO ID: D0036), participating under the REACH model.

Doughney's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 759 traditional Medicare patients, billed 109,378 HCPCS/CPT codes, and received $1,431,520 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,355 prescription claims across 285 beneficiaries totaling $2,021,651 in drug costs, led by Revlimid (Lenalidomide). DME data shows 43 claims. Open Payments data shows 70 records totaling $1,475. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $1,608,301 and ending at $2,021,651. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	750	154,108	$2,279,349
2016	783	128,552	$2,233,031
2017	806	139,976	$2,781,871
2018	817	179,403	$3,432,659
2019	916	249,400	$3,490,906
2020	855	200,794	$2,871,948
2021	890	198,747	$3,303,237
2022	828	157,066	$2,742,466
2023	764	134,878	$1,973,761
2024	759	109,378	$1,431,520

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	193	1,202	$1,608,301
2016	207	1,086	$1,291,108
2017	215	1,277	$1,841,521
2018	236	1,204	$1,387,334
2019	226	1,233	$1,808,358
2020	214	1,118	$2,165,602
2021	227	1,275	$1,802,504
2022	258	1,360	$2,173,562
2023	254	1,258	$1,510,667
2024	285	1,355	$2,021,651

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	79	$47,007
2016	N/R	50	$20,499
2017	N/R	50	$8,423
2018	N/R	14	$5,327
2019	N/R	41	$5,055
2020	N/R	40	$2,502
2021	N/R	61	$2,951
2022	N/R	31	$950
2023	N/R	54	$10,942
2024	N/R	43	$822

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	208	517	$92
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	272	386	$63
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	148	188	$13
36415	Insertion of needle into vein for collection of blood sample	561	1,283	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	561	1,331	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	15	420	$343,503
Ibrance	Palbociclib	13	588	$331,736
Lenalidomide	Lenalidomide	16	448	$204,660
Sprycel	Dasatinib	22	660	$191,486
Imbruvica	Ibrutinib	12	360	$137,901

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	19	$521
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	24	$301

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	70	$1,475	Celgene Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Kathleen Bridget Doughney, MD?

Tedicare shows public-source Medicare data for Kathleen Bridget Doughney, MD (NPI 1093729287), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Kathleen Bridget Doughney, MD have ACO affiliation data?

Kathleen Bridget Doughney, MD is shown with ACO affiliation data for Complete Health Accountable Care LLC (REACH, ACO ID D0036).

What billing organization is linked to Kathleen Bridget Doughney, MD?

Kathleen Bridget Doughney, MD is linked to FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (billing NPI 1760590962) in the available physician profile data.

Does Kathleen Bridget Doughney, MD have Open Payments data?

Kathleen Bridget Doughney, MD has 70 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.